Ed Miner, MD, FACC
Utah, Chapter President
ACC Governor, Utah

Rockies Chapter Meeting Please join your cardiology colleagues at the ACC Rockies Chapter Meeting in Park City, Utah for updates on ACC affairs, the potential new CV Board, and clinical topics such as Genetic and Sports EP, plus a discussion on the growing role of obesity medications in heart failure, and the first-ever Cardiology State-of-the-State report. There will be many opportunities for networking, as well!. For more information and to register, please visit: ACC Rockies Chapter Meeting 2025

ACC Live Courses
For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings

RSS Latest in Cardiology from ACC.org

  • PRO-TAVI: Should High-Risk Patients Undergo PCI Before TAVI?
    Older patients with coronary artery disease (CAD) for whom PCI was deferred until after TAVI had similar outcomes as those for whom it was not deferred, according to findings from the PRO-TAVI study presented in a Late-Breaking Clinical Trial session...
  • TRI-FR: T-TEER Reduces HF Hospitalization, More in Patients With Severe TR
    Transcatheter tricuspid edge-to-edge repair (T-TEER) in addition to standard-of-care medical therapy reduced the risk of death, myocardial infarction (MI), stroke and hospitalization for heart failure (HF) compared with standard-of-care alone in patients with severe symptomatic tricuspid regurgitation (TR)...
  • PROTECT H2H: Emboliner vs. Sentinel Embolic Protection Devices in TAVR
    In the first head-to-head comparison of two embolic protection devices used during TAVR, the investigational Emboliner protection catheter performed comparably to the U.S. Food and Drug Administration (FDA)-approved Sentinel cerebral protection system relative to the composite primary endpoint and secondary endpoint of stroke, according to results from the PROTECT H2H trial presented during a Late-Breaking […]
  • SURVIV: mViV vs. rMVR For Mitral Bioprosthetic Valve Dysfunction
    Among patients with a failed mitral bioprosthetic valve, transcatheter mitral valve-in-valve (mVIV) treatment was associated with a lower rate of death or disabling stroke at one year compared with standard repeat mitral valve replacement surgery (rMVR), according to results from the SURVIV study presented during a Late-Breaking Clinical Trial session at ACC.26 in New Orleans.
  • ALERT: Electronic Notifications Improve Management of AS, MR
    Electronic clinician notification alerts were shown to be effective in improving the timely evaluation and treatment of patients with severe aortic stenosis (AS) or mitral regurgitation (MR), according to the ALERT trial presented during a Featured Clinical Research session...